期刊文献+

miRNA-148a 在膀胱癌组织中的表达及生物信息学分析 被引量:5

Expression of miRNA-148a in Bladder Carcinoma Tissues and Its Bioinformatics Analysis
下载PDF
导出
摘要 目的:探索 miRNA-148a 在膀胱癌发生发展中的作用。方法收集35例膀胱癌组织和16例非癌组织,采用荧光定量 PCR 方法检测 miRNA-148a 的相对表达量,并分析其与临床特征的相关性;采用生物信息学分析,预测 miRNA-148a的靶基因和转录因子,构建 TF-miRNA-148a-靶基因调控网络图,并对其靶基因进行 GO 富集和 KEGG Pathway 分析。结果miRNA-148a 在膀胱癌中的相对表达量(0.0008±0.0002)明显低于非癌组织(0.0021±0.0005)(t=2.46,P <0.05),其相对表达量在不同性别、年龄、病理分级、临床分期、淋巴结转移组的差异无统计学意义(P >0.05)。3个软件都预测到的 miRNA-148a 靶基因268个;预测到 miRNA-148a 的转录因子60个,结合评分>80的结合位点657个;对268个靶基因进行 GO 富集分析,发现其靶基因主要涉及神经细胞分化、发育、增殖、mRNA 合成,蛋白连接等众多的生物学过程(P <0.001,相对于背景具有统计意义);KEGG Pathway 分析发现268个靶基因参与 p53,恶性肿瘤、前列腺癌、PI3K-AKT 等信号通路(P <0.05,相对于背景具有统计意义);根据构建的 TF-miRNA-148a-靶基因调控网络图,挖掘出可能调控 miRNA-148a 的转录因子有 SP1,ESR1,AP1,MYC,BRCA1等;可能受 miRNA-148a 调控的基因有 IGF1,P27 kip1,NCOA1,PTEN, SERPINE1等。结论miRNA-148a 在膀胱癌中表达下调,可能参与膀胱癌的发生发展,生物信息学分析为后续研究提供一定的思路。 Objective To explore the role of miRNA-148a in bladder tumorous development and progression.Methods Ex-pression of miRNA-148a was assessed in 35 bladder carcinoma tissues and 16 non-carcinoma tissues by fluorescence quanti-tative real time PCR,and correlation with clinical features was evaluated.Target genes and transcription factors of miRNA-148a were predicted using bioinformatic analysis,then TF-miRNA-148a-target genes network diagram was built and the tar-get genes was analyzed of gene ontology enrichment and KEGG pathway.Results Expression of miRNA-148a was lower in bladder carcinoma tissues than in non-carcinoma tissues(0.000 8±0.000 2 vs 0.002 1±0.000 5)(t=2.46,P 〈0.05),but its expression was no statistical significance in different groups of gender,age,pathological classification,clinical stage, lymph node metastasis (P 〉0.05).268 target genes of miRNA-148a were predicted by three softwares at the same time,60 transcription factors were predicted and the binding sites with combination scroes above 80 was 657.The target genes of miRNA-148a was enriched in many biological processes,such as neuron differentiation,generation of neurons,neuron projec-tion development,cytoplasmic mRNA processing body,cytoplasm(P 〈0.001).They also participated in p53 signaling path-way,proteoglycans in cancer-homo sapiens,pathways in cancer,prostate cancer,protein processing in endoplasmic reticulum, focal adhesion and so on(P 〈0.05).According to TF-miRNA-148a-target genes network diagram,miRNA-148a was regula-ted by SP1,ESR1,AP1,MYC and BRCA1,genes of IGF1,P27kip1 ,NCOA1,PTEN,SERPINE1 might be regulated by miR-NA-148a.Conclusion miRNA-148a which was significantly down-regulation in bladder carcinoma tissues may be participate in bladder tumorous development and progression,bioinformatics analysis provides some ideas for further research.
出处 《现代检验医学杂志》 CAS 2015年第4期6-9,13,共5页 Journal of Modern Laboratory Medicine
基金 国家自然科学基金面上项目(81372151).
关键词 膀胱癌 miRNA-148a 生物信息学 bladder carcinoma miRNA-148a bioinformatics
  • 相关文献

参考文献18

  • 1Osman A. MicroRNAs in health and disease-basic sci- ence and clinical applicationsrJ3. Clin Lab, 2012,58 (5/6) :393-402.
  • 2蒋永容,陈川,张志敏,郑继军,许文,罗美林,戴楠,李梦侠,杨宇馨,李增鹏,王东,王阁.miRNA-122a靶基因预测及生物信息学分析[J].中国肿瘤临床,2011,38(16):931-934. 被引量:6
  • 3Chiyomaru T, Enokida H,Tatarano S, et al. miRNA- 145 and miRNA-133a function as turnout suppressors and directly regulate FSCN1 expression in bladder cancer[J]. Br J Cancer,2010,102(5) :883-891.
  • 4Lin T, Dong W, Huang J, et al. MieroRNA-143 as a tumor suppressor for bladder cancer[J]. J Urol, 2009, 181 (3) : 1372-1380.
  • 5Iehimi T, Enokida H, Okuno Y, et al. Identification of novel mieroRNA targets based on mieroRNA signa- tures in bladder cancer[J]. International Journal of Cancer,2009,125(2) :345-352.
  • 6Baffa R, Fassan M, Volinia S, et al. MieroRNA ex- pression profiling of human metastatic cancers identi- fies cancer gene targets[J]. J Pathol, 2009,219 (2) : 214-221.
  • 7Wang Y,Luo HM,Li Y,et al. hsa-miRNA-96 up-reg- ulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas [J ]. Molecular Medicine Re- ports, 2012,5 (1) : 260-265.
  • 8Song YX, Yue ZY, Wang ZN, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell prolifera- tion[J]. Mol Cancer, 2011 (10) : 1.
  • 9Zhang H, Li Y, Huang Q, et al. MiRNA-148a pro- motes apoptosis by targeting Bcl-2 in colorectal cancer [J]. Cell Death Differ,2011,18(11) .. 1702-1710.
  • 10Hummel R, Hussey DJ, Michael MZ, et al. MiRNAs and their association with locoregional staging and survival following surgery foresophageal carcinoma [J]. Ann Surg Oncol,2011,18(1) :253-260.

二级参考文献31

  • 1宋毅,吴关,辛殿旗,那彦群.神经内分泌分化对前列腺癌细胞生长及雄激素受体表达影响的实验研究[J].中华外科杂志,2004,42(23):1453-1456. 被引量:4
  • 2SCHRODER F H. Progress in understanding androgenindependent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms[J]. Eur Urol, 2008, 53(6): 1129-1137.
  • 3CHOW C. OncomiRs: the discovery and progress of microRNAs in cancers[J].Mol Cancer, 2007, 6: 60.
  • 4BONKHOFF H, FIXEMER T. Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype[J]. Pathologe, 2005, 26 (6) 453-460.
  • 5MURATA T, TAKAYAMA K, KATAYAMA S, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression[J]. Prostate Cancer Prostatic Dis, 2010,13 (4) : 356-361.
  • 6FUJITA Y, KOJIMA K, OHHASHI R, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drugresistant prostate cancer PC3 cells by regulating MSK1 expression[J]. J Biol Chem, 2010, 285(25):19076-19084.
  • 7ZHANG B, PAN X, COBB G P, et al. microRNAs as oncogenes and tumor suppressors[J]. Dev Biol, 2007, 302 (1): 1-12.
  • 8KRUTZFELDT J, RAJEWSKY N, BRAICH R, et al. Silencing of mieroRNAs in vivo with ' antagomirs' [J]. Nature, 2005, 438(7068): 685-689.
  • 9SONG Y X, YUE Z Y, WANG Z N, et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation [J]. Mol Cancer, 2011, 10: 1.
  • 10ZHANG H, LI Y, HUANG Q, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer [J]. Cell Death Differ, 2011 Apr 1. [Epub ahead of print].

共引文献7

同被引文献36

  • 1Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer [J]. Science, 2005, 310 (5748) : 644-648.
  • 2Levett PN. Leptospirosis[J]. Clin Microbiol Rev, 2001,14(2) : 296-326.
  • 3Lo YM, Corbetta N, Chamberlain PF, et al. Prese- nce of fetal DNA in maternal plasma and serum[J]. Lancet,1997,350(9076):485-487.
  • 4Henter JI, Horne A, Arice M, et al. HLH-2004 : di- agnostic and therapeutic guidelines for hemophago- cytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007,48(2) : 124-131.
  • 5Hamilton SR, Liu B, Parsons RE, et al. The molecu- lar basis of Tureot's syndrome[J]. N Engl J Med, 1995,332(13) : 839-847.
  • 6Richard P,Charron P,Carrier L,et al. Hypertrophic cardiomyopathy: distribution of disease genes, spec- trum of mutations, and implications for a molecular diagnosis strategy[J]. Circulation, 2003, 107 (17) : 2227-2232.
  • 7Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis[J]. N Engl J Med,1993,329(27) :1982-1987.
  • 8Yates CR, Krynetski EY, Loennechen T, et al. Mo- lecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercap- topurine intolerance[J]. Ann Intern Med, 1997,126 (8) :608-614.
  • 9Rosenwald A,Wright G,Wiestner A,et al. The pro- liferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma[J]. Cancer Cell, 2003, 3 (2) : 185-197.
  • 10Choi M,Scholl UI,Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing[J]. Proc Natl Acad Sci USA, 2009,106 (45) : 19096-19101.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部